Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS - Euronext Lisbon - PTIBS0AM0008 - Common Stock - Currency: EUR

9.49  +0.01 (+0.11%)

Fundamental Rating

4

Overall IBS gets a fundamental rating of 4 out of 10. We evaluated IBS against 60 industry peers in the Hotels, Restaurants & Leisure industry. Both the profitability and the financial health of IBS get a neutral evaluation. Nothing too spectacular is happening here. IBS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year IBS was profitable.
In the past year IBS had a positive cash flow from operations.
IBS had positive earnings in 4 of the past 5 years.
IBS had a positive operating cash flow in each of the past 5 years.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

IBS has a Return On Assets (2.32%) which is in line with its industry peers.
IBS has a Return On Equity of 4.95%. This is in the better half of the industry: IBS outperforms 61.67% of its industry peers.
IBS has a Return On Invested Capital (3.03%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for IBS is significantly below the industry average of 11.95%.
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROIC 3.03%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

1.3 Margins

Looking at the Profit Margin, with a value of 3.72%, IBS is in line with its industry, outperforming 56.67% of the companies in the same industry.
In the last couple of years the Profit Margin of IBS has declined.
Looking at the Operating Margin, with a value of 4.91%, IBS is in line with its industry, outperforming 48.33% of the companies in the same industry.
IBS's Operating Margin has declined in the last couple of years.
IBS has a Gross Margin (48.89%) which is in line with its industry peers.
IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IBS is destroying value.
Compared to 1 year ago, IBS has about the same amount of shares outstanding.
The number of shares outstanding for IBS has been increased compared to 5 years ago.
Compared to 1 year ago, IBS has a worse debt to assets ratio.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 1.99 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
IBS's Altman-Z score of 1.99 is in line compared to the rest of the industry. IBS outperforms 60.00% of its industry peers.
IBS has a debt to FCF ratio of 6.77. This is a slightly negative value and a sign of low solvency as IBS would need 6.77 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.77, IBS is in line with its industry, outperforming 55.00% of the companies in the same industry.
IBS has a Debt/Equity ratio of 0.69. This is a neutral value indicating IBS is somewhat dependend on debt financing.
The Debt to Equity ratio of IBS (0.69) is better than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Altman-Z 1.99
ROIC/WACC0.46
WACC6.55%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

IBS has a Current Ratio of 1.38. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
IBS has a Current ratio of 1.38. This is in the better half of the industry: IBS outperforms 78.33% of its industry peers.
A Quick Ratio of 1.28 indicates that IBS should not have too much problems paying its short term obligations.
IBS has a Quick ratio of 1.28. This is in the better half of the industry: IBS outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.28
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.97%.
Measured over the past years, IBS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.58% on average per year.
IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.51%.
Measured over the past years, IBS shows a decrease in Revenue. The Revenue has been decreasing by -1.46% on average per year.
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%

3.2 Future

IBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.95% yearly.
Based on estimates for the next years, IBS will show a small growth in Revenue. The Revenue will grow by 7.32% on average per year.
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y7.32%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 23.72, the valuation of IBS can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of IBS indicates a somewhat cheap valuation: IBS is cheaper than 66.67% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.35. IBS is around the same levels.
IBS is valuated rather expensively with a Price/Forward Earnings ratio of 22.37.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IBS indicates a somewhat cheap valuation: IBS is cheaper than 61.67% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.20, IBS is valued at the same level.
Industry RankSector Rank
PE 23.73
Fwd PE 22.37
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IBS is valued cheaper than 83.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.22
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IBS does not grow enough to justify the current Price/Earnings ratio.
IBS's earnings are expected to grow with 17.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)9.81
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y17.27%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.34%, IBS is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.98, IBS pays a better dividend. On top of this IBS pays more dividend than 95.00% of the companies listed in the same industry.
IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
Industry RankSector Rank
Dividend Yield 5.34%

5.2 History

On average, the dividend of IBS grows each year by 31.58%, which is quite nice.
Dividend Growth(5Y)31.58%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 0.2 0.4 0.6

5.3 Sustainability

122.87% of the earnings are spent on dividend by IBS. This is not a sustainable payout ratio.
IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP122.87%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (5/28/2025, 5:19:05 PM)

9.49

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)05-30 2025-05-30
Inst Owners23.23%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap393.93M
Analysts80
Price Target12.16 (28.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.34%
Yearly Dividend0.7
Dividend Growth(5Y)31.58%
DP122.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.44%
Min EPS beat(2)-25.74%
Max EPS beat(2)-15.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)0.18%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)6.97%
Min Revenue beat(4)0.18%
Max Revenue beat(4)10.27%
Revenue beat(8)6
Avg Revenue beat(8)5.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.56%
PT rev (3m)2.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 23.73
Fwd PE 22.37
P/S 0.87
P/FCF 9.22
P/OCF 5.11
P/B 1.15
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)0.4
EY4.21%
EPS(NY)0.42
Fwd EY4.47%
FCF(TTM)1.03
FCFY10.84%
OCF(TTM)1.86
OCFY19.55%
SpS10.95
BVpS8.22
TBVpS5.89
PEG (NY)9.81
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROCE 3.84%
ROIC 3.03%
ROICexc 4.07%
ROICexgc 5.24%
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
FCFM 9.4%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
ROICexc(3y)6.92%
ROICexc(5y)N/A
ROICexgc(3y)9.56%
ROICexgc(5y)N/A
ROCE(3y)5.99%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-20.96%
ROICexc growth 3YN/A
ROICexc growth 5Y-13.96%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.55%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 252.85%
Current Ratio 1.38
Quick Ratio 1.28
Altman-Z 1.99
F-Score6
WACC6.55%
ROIC/WACC0.46
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)12.95%
Cap/Sales(5y)11.86%
Profit Quality(3y)143.97%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y7.32%
EBIT growth 1Y-21.52%
EBIT growth 3YN/A
EBIT growth 5Y-7.51%
EBIT Next Year304.41%
EBIT Next 3Y79.23%
EBIT Next 5Y62.33%
FCF growth 1Y-28.97%
FCF growth 3YN/A
FCF growth 5Y20.7%
OCF growth 1Y-29.99%
OCF growth 3Y45.49%
OCF growth 5Y10.5%